Maravai LifeSciences Holdings Inc (MRVI)
10.85
+0.07
(+0.65%)
USD |
NASDAQ |
May 24, 16:00
10.86
0.00 (0.00%)
After-Hours: 20:00
Maravai LifeSciences Holdings Cash from Financing (TTM): -42.44M for March 31, 2024
Cash from Financing (TTM) Chart
Historical Cash from Financing (TTM) Data
Date | Value |
---|---|
March 31, 2024 | -42.44M |
December 31, 2023 | -61.09M |
September 30, 2023 | -127.68M |
June 30, 2023 | -165.91M |
March 31, 2023 | -166.18M |
December 31, 2022 | -187.50M |
September 30, 2022 | -170.96M |
Date | Value |
---|---|
June 30, 2022 | -184.80M |
March 31, 2022 | -175.51M |
December 31, 2021 | -159.05M |
September 30, 2021 | -68.80M |
June 30, 2021 | -18.46M |
March 31, 2021 | 14.82M |
December 31, 2020 | 53.21M |
Cash From Financing Definition
Cash flow from financing is a major line item of the statement of cash flows. This metric tracks the movement of cash flows for the overall financing activities of the company. A few examples of financing activities include common stock issuance, total dividends paid, and net debt issuance.
Cash from Financing (TTM) Range, Past 5 Years
-187.50M
Minimum
Dec 2022
53.21M
Maximum
Dec 2020
-104.31M
Average
-143.37M
Median
Cash from Financing (TTM) Benchmarks
Bio-Techne Corp | -86.52M |
Mersana Therapeutics Inc | 78.96M |
Royalty Pharma PLC | -2.150B |
Longboard Pharmaceuticals Inc | 295.24M |
Caribou Biosciences Inc | 165.14M |